Dr. Ruan on the Evolving Armamentarium in MCL

Partner | Cancer Centers | <b>Weill Cornell Sandra & Edward Meyer Cancer Center</b>

Jia Ruan, MD, PhD, discusses the evolving armamentarium ​in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the evolving armamentarium ​in mantle cell lymphoma (MCL).

Chemoimmunotherapy has been a historical ​treatment approach ​for patients with MCL, says Ruan. However, over the past few years, treatment has evolved to ​incorporate effective, low​-intensity, oral-based strategies, which are being used in the outpatient setting​, Ruan explains. These therapies can be used in induction regimens or as treatment in the relapsed/refractory setting, Ruan says.

This shift has been revolutionary in the field of MCL​, says Ruan. Therapy ​has become more convenient and accessible for ​the majority of patients, regardless of age and comorbidities.

This treatment approach will ​hopefully continue to benefit patients ​by extending remission duration and improving survival outcome for many years to come, Ruan concludes.